Jazz Pharmaceuticals Acquires GW Pharmaceuticals for $7.2 billion

Jazz Pharmaceuticals Acquires Chimerix for About $935 Million

March 5, 2025

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire Chimerix in an all-cash transaction valued at approximately $935 million (about $8.55 per share). The deal is expected to close in the second quarter of 2025, pending customary closing conditions, including tender of shares in a tender offer.

Pfizer Acquires Global Blood Therapeutics (GBT) for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer entered into a definitive agreement to acquire Global Blood Therapeutics (GBT), paying $68.50 per share in cash for an enterprise value of about $5.4 billion. The deal adds GBT’s sickle cell disease portfolio, including Oxbryta (voxelotor), along with clinical pipeline assets such as GBT021601 (GBT601) and inclacumab.

CNX Therapeutics Acquires Sativex from Jazz Pharmaceuticals

October 31, 2025

Pharmaceuticals

CNX Therapeutics has acquired the global Sativex (nabiximols) business from Jazz Pharmaceuticals, with the deal closing on 31 October 2025. The transaction includes marketing authorisations and commercial rights worldwide and the UK entity SVX Therapeutics Limited; Jazz will support a transition period under a Transition Service Agreement.

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Pharmaceuticals

Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.

22nd Century Group Acquires RX Pharmatech Ltd

January 24, 2023

Food & Beverage

22nd Century Group, through its GVB Biopharma business, acquired UK-based RX Pharmatech Ltd, a distributor of cannabinoid/CBD products and holder of numerous U.K. novel food applications. The deal includes $650,000 up-front in cash and stock plus a three-year equity earn-out tied to revenue milestones and aims to strengthen 22nd Century's access and distribution in the U.K. and EU consumer CBD market.